Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Estyme Lift is a cross-linked hyaluronic acid (HA) dermal filler containing lidocaine, developed for facial aesthetic procedures. It is designed to add volume to tissue, restore skin contours, and correct moderate to severe nasolabial folds by injection into the dermis or hypodermis. The product utilizes proprietary C-HA.PURE TECHNOLOGY™, a cold temperature cross-linking process that preserves the natural structure of HA while requiring less BDDE (a common cross-linker), aiming for improved safety and efficacy. Clinical trials have demonstrated its non-inferiority and even statistical superiority over established HA-lidocaine fillers in improving wrinkle severity scores at 3 and 6 months post-injection. Estyme Lift is CE marked under EU Medical Device Regulation as a Class IV medical device, with ANVISA authorization in Brazil, and is marketed as Evolysse Lift in the United States[2][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Estyme Lift.